{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T07:55:09Z","timestamp":1791446109173,"version":"4.3.3"},"reference-count":22,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:00:00Z","timestamp":1785110400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:00:00Z","timestamp":1785110400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Dermatology"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    Topical bexarotene 1% gel is an approved skin\u2010directed treatment for refractory or persistent stage IA\u2010IB cutaneous T\u2010cell lymphoma, but real\u2010world evidence in mycosis fungoides (MF), particularly regarding maintenance use after complete response, remains limited. We retrospectively reviewed 56 patients with histopathologically and immunohistochemically confirmed, previously treated stage IA\u2010IB MF who received topical bexarotene between 2009 and 2022. Clinical response, post\u2010treatment biopsy findings, adverse events, maintenance therapy, and relapse outcomes were analyzed. The cohort included 31 women and 25 men; 42 patients (75.0%) had stage IA and 14 (25.0%) had stage IB disease. Complete response (CR) was achieved in 20 patients (35.7%) and partial response in 15 (26.8%), yielding an overall response rate of 62.5%. Overall response was higher in stage IA than in stage IB disease (73.8% vs. 28.6%;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.003) and in T1a than in T2a disease (77.1% vs. 36.4%;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.044). All biopsied complete responders showed no MF\u2010compatible histology. Adverse events were exclusively local and manageable. Among 18 evaluable complete responders, relapse occurred in 15 (83.3%). Median time to relapse was longer with maintenance topical bexarotene than without maintenance (45 vs. 30\u2009weeks;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.039). Topical bexarotene appears effective and well tolerated in previously treated stage IA\u2010IB MF, with greatest benefit in limited patch\u2010stage disease. Maintenance use after CR may delay relapse, but this exploratory finding requires prospective validation.\n                  <\/jats:p>","DOI":"10.1111\/1346-8138.70431","type":"journal-article","created":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T03:57:00Z","timestamp":1785211020000},"page":"1457-1464","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy, Safety, and Maintenance Use of Topical Bexarotene in Early\u2010Stage Mycosis Fungoides: A Single\u2010Center Retrospective Real\u2010World Study"],"prefix":"10.1111","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-0080-7133","authenticated-orcid":false,"given":"Fatich","family":"Memet","sequence":"first","affiliation":[{"name":"Department of Dermatology and Venereology Kocaeli University Faculty of Medicine  Kocaeli T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6617-0019","authenticated-orcid":false,"given":"Dilek","family":"Bayramg\u00fcrler","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venereology Kocaeli University Faculty of Medicine  Kocaeli T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3419-9084","authenticated-orcid":false,"given":"Abdullah","family":"Demirba\u015f","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venereology Kocaeli University Faculty of Medicine  Kocaeli T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8120-9548","authenticated-orcid":false,"given":"Evren Odyakmaz","family":"Demirsoy","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venereology Kocaeli University Faculty of Medicine  Kocaeli T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8137-2126","authenticated-orcid":false,"given":"Aysun \u015eikar","family":"Akt\u00fcrk","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venereology Kocaeli University Faculty of Medicine  Kocaeli T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nilg\u00fcn","family":"Sayman","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venereology Kocaeli University Faculty of Medicine  Kocaeli T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9515-1682","authenticated-orcid":false,"given":"Rebiay","family":"K\u0131ran","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venereology Kocaeli University Faculty of Medicine  Kocaeli T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,7,27]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-03-055749"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2023.113343"},{"key":"e_1_2_9_4_1","unstructured":"National Comprehensive Cancer Network \u201cNCCN Clinical Practice Guidelines in Oncology: Primary Cutaneous Lymphomas. Version 2.2025 \u201dPlymouth Meeting PA: National Comprehensive Cancer Network (2025)."},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy133"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.17240"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25577"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-025-01511-1"},{"key":"e_1_2_9_9_1","unstructured":"\u201cTargretin (Bexarotene) Gel 1% [Prescribing Information]. DailyMed \u201daccessed May 2026."},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.138.3.325"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(03)01475-0"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0040296"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.0630"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.abd.2024.04.011"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1001\/2013.jamadermatol.541"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1159\/000516138"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2023.08.020"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1298296"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2020.10.007"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2018.5905"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15661"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2022.02.002"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16283"}],"container-title":["The Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1346-8138.70431","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/1346-8138.70431","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1346-8138.70431","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T07:35:51Z","timestamp":1791444951000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1346-8138.70431"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,27]]},"references-count":22,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10.1111\/1346-8138.70431"],"URL":"https:\/\/doi.org\/10.1111\/1346-8138.70431","archive":["Portico"],"relation":{},"ISSN":["0385-2407","1346-8138"],"issn-type":[{"value":"0385-2407","type":"print"},{"value":"1346-8138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,27]]},"assertion":[{"value":"2026-06-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}